Coya Therapeutics, Inc. (NASDAQ:COYA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have earned a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $15.3333.

A number of equities research analysts have recently issued reports on COYA shares. Chardan Capital reissued a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Friday, July 17th. BTIG Research reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Coya Therapeutics in a research note on Tuesday, September 15th. Roth Capital reaffirmed a “buy” rating and set a $12.00 price objective on shares of Coya Therapeutics in a research report on Monday, August 24th. Finally, HC Wainwright reissued a “buy” rating on shares of Coya Therapeutics in a research note on Monday, August 24th.

Coya Therapeutics Price Performance

COYA stock opened at $4.89 on Tuesday. The company has a market cap of $114.72 million, a P/E ratio of -4.57 and a beta of 0.61. Coya Therapeutics has a 1 year low of $3.71 and a 1 year high of $7.75. The stock’s fifty day moving average price is $4.61 and its 200-day moving average price is $4.66.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. Coya Therapeutics had a negative return on equity of 52.05% and a negative net margin of 270.22%.The company had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.13 million. As a group, analysts expect that Coya Therapeutics will post -1.34 earnings per share for the current year.

Institutional Investors Weigh In On Coya Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC grew its position in shares of Coya Therapeutics by 55.4% during the first quarter. Renaissance Technologies LLC now owns 103,964 shares of the company’s stock worth $410,000 after purchasing an additional 37,064 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Coya Therapeutics by 205.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 95,919 shares of the company’s stock worth $377,000 after purchasing an additional 64,490 shares during the period. ADAR1 Capital Management LLC purchased a new stake in Coya Therapeutics during the 1st quarter valued at approximately $161,000. Long Corridor Asset Management Ltd purchased a new stake in Coya Therapeutics during the 4th quarter valued at approximately $225,000. Finally, Cetera Investment Advisers raised its position in shares of Coya Therapeutics by 36.4% during the first quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock valued at $118,000 after buying an additional 8,000 shares during the last quarter. 39.75% of the stock is owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies designed to enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune responses and may play a role in limiting inflammation associated with neurodegenerative and autoimmune diseases.

The company’s pipeline includes investigational Treg-based therapies, including COYA 301, an autologous Treg therapy being evaluated for potential use in conditions such as amyotrophic lateral sclerosis (ALS).